Trial Profile

A Pivotal Phase 3 Study of OCU 310 in Patients with Chronic Dry Eye Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 12 Apr 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brimonidine/loteprednol-etabonate (Primary)
Indications Dry eyes
Focus Adverse reactions; Registrational; Therapeutic Use
Sponsors Ocugen

Most Recent Events

08 Apr 2019 According to an Ocugen media release, company is waiting for a full dataset from this trial and will provide an update once they complete full analysis.
08 Apr 2019 Status changed from recruiting to completed, according to a Histogenics Corporation media release.
01 Oct 2018 According to an Ocugen media release, topline data are expected in in the second half of 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com